Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
1 study found for:    INCB 18424-261
Show Display Options
Rank Status Study
1 Completed
Has Results
Alternative Dosing Strategy of Ruxolitinib in Patients With Myelofibrosis
Conditions: Primary Myelofibrosis;   Post-Polycythemia Vera Myelofibrosis;   Post-Essential Thrombocythemia Myelofibrosis
Intervention: Drug: Ruxolitinib

Study has passed its completion date and status has not been verified in more than two years.